On April 21, 2020, AIM ImmunoTech Inc. entered into a Mutual Confidentiality Agreement with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. (collectively, the "Entities") for the purpose of evaluation and discussion for certain business relationships concerning a COVID-19 therapeutic and vaccine. Current discussions with the Entities are preliminary and we anticipate that, if the parties determine to proceed, initial activity will consist of preclinical animal studies of Ampligen.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.399 USD | -2.68% | -0.68% | -9.77% |
May. 16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
Apr. 29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.77% | 20.86M | |
+10.53% | 114B | |
+12.99% | 107B | |
-5.23% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.59% | 17.51B | |
-39.36% | 17.17B | |
+7.17% | 14.14B | |
+35.09% | 12.2B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM ImmunoTech Inc. Enters into Mutual Confidentiality Agreement with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd